|4.||Critical Illness (Critically Ill)
|1.||Walsh, Thomas J: 16 articles (12/2015 - 03/2002)|
|2.||Nucci, Marcio: 13 articles (10/2014 - 03/2002)|
|3.||Colombo, Arnaldo Lopes: 11 articles (07/2013 - 12/2002)|
|4.||Garey, Kevin W: 9 articles (09/2015 - 05/2006)|
|5.||Clancy, Cornelius J: 8 articles (01/2016 - 08/2005)|
|6.||Colombo, Arnaldo L: 8 articles (10/2014 - 05/2006)|
|7.||Kontoyiannis, Dimitrios P: 8 articles (06/2014 - 04/2002)|
|8.||Reboli, Annette C: 8 articles (01/2014 - 02/2007)|
|9.||Pappas, Peter G: 8 articles (01/2014 - 05/2003)|
|10.||Nguyen, M Hong: 7 articles (01/2016 - 08/2005)|
12/01/2010 - "Anidulafungin was effective in the treatment of patients with documented candidemia arising from different sites, and no significant side effects were observed."
11/01/2005 - "In a phase 2 open-label, dose-ranging study in patients with candidemia, anidulafungin was effective in eradicating Candida albicans and other species of Candida. "
01/01/2013 - "Anidulafungin has been reported to be an effective treatment for candidemia in Western populations, but little is known about its efficacy in Asian patients, where the clinical presentation and epidemiology may be different. "
11/01/2006 - "This pharmacokinetic-pharmacodynamic picture of anidulafungin persistence in tissues and the resultant persistent fungal decline should be exploited to improve the efficacy of anidulafungin therapy for candidemia."
01/01/2013 - "An open-label study of anidulafungin for the treatment of candidemia was recently conducted in several Asian countries. "
|2.||Fluconazole (Zonal)FDA LinkGeneric
01/01/2000 - "Fluconazole was administered as the first line agent in 6 episodes and successfully cleared candidemia in 5 episodes. "
01/01/2013 - "Candida glabrata is an emerging pathogen in private institutions and in this setting, fluconazole should not be considered as a safe option for primary therapy of candidemia."
11/01/2013 - "The purpose of this study was to depict the epidemiologic and clinical characteristics of candidemia due to these emerging fluconazole less susceptible species. "
06/01/2012 - "The objective of this study was to evaluate the effects of prior fluconazole therapy, including the dose and duration, on fluconazole susceptibility among Candida species isolated from hospitalized patients with candidemia. "
08/01/2010 - "Previous studies have sought to determine the risk factors associated with candidemia caused by non-albicans Candida spp. or with potentially fluconazole-resistant Candida spp. (C. "
|3.||Amphotericin B (Amphotericin)FDA LinkGeneric
06/01/1995 - "Eighteen episodes (two episodes in 1 patient) of candidemia were cured using 7 to 14 days of amphotericin B therapy after the last positive blood culture. "
06/01/1995 - "To determine the efficacy of short-course (7 to 14 days of therapy after the last positive blood culture) amphotericin B therapy for candidemia in children. "
02/01/2009 - "In this study, the susceptibility to amphotericin B of Candida spp. isolates obtained from patients with candidemia was related to their respective clinical outcomes. "
05/01/1997 - "A protocol amendment implemented midway through the trial required patients to be removed from the study and treated with amphotericin B if species identification indicated candidemia due to Candida glabrata or Candida krusei. "
03/01/2014 - "Amphotericin B has been recommended as the primary treatment; however, its use is limited due to drug-induced nephrotoxicity and amphotericin B-resistant candidemia. "
|4.||micafungin (FK463)FDA Link
11/01/2003 - "Micafungin is effective against candidemia due to C. "
10/01/2005 - "Micafungin shows promise as a safe and effective agent for the treatment of newly diagnosed and refractory cases of candidemia. "
04/01/2005 - "It is suggested that micafungin is useful for the treatment of candidemia associated with Candida parapsilosis."
10/01/2005 - "Efficacy of micafungin for the treatment of candidemia."
01/01/2014 - "Thus, based on the results of the present study, the optimal micafungin dose for the treatment of candidemia appears to range from 100 to 150 mg/d, as recommended by the Guidelines."
|5.||caspofungin (Cancidas)FDA Link
03/01/2004 - "The addition of caspofungin resulted in rapid clearance of the candidemia. "
01/01/2014 - "Secondary antifungal prophylaxis with caspofungin was found effective in treating six FN episodes in three patients who had experienced at least two persistent candidemia attacks. "
05/01/2011 - "In the analyzed period, among 307 children who underwent surgical procedures, we observed 2 cases of candidemia (0.65%) which were effectively cured with caspofungin. "
03/01/2014 - "Caspofungin successfully treated persistent candidemia in extremely premature infants at 23 and 24 weeks' gestational age."
03/01/2014 - "There was no recurrent candidemia after discontinuing caspofungin. "
05/01/2001 - "Most isolates from the bloodstreams of neonates with candidemia were susceptible to antifungal agents tested but a low MIC of the antifungal agent did not predict successful therapy in this study. "
09/01/2015 - "Improved treatment of candidemia may ultimately be achieved by optimizing the use of antifungal agents rather than the development of new drugs."
10/01/2003 - "Given the continuing progress in clinical research infrastructure and development of new diagnostic tests and antifungal agents, substantial improvement in the prevention, diagnosis, and management of neonatal candidemia is plausible over the next decade."
04/01/2014 - "The purpose of this study is to investigate the risk factors and susceptibilities to antifungal agents of Candida albicans and Candida non-albicans species (spp.) in candidemia cases in Kobe University Hospital. "
07/01/2012 - "The goals of this study were to estimate the costs directly associated with the treatment of candidemia and factors associated with increased costs, as well as the impact of first-line antifungal agents on the outcomes and costs. "
11/01/2015 - "Echinocandins have in vitro activity against most Candida spp. and are the first-line agents in the treatment of candidemia. "
10/01/2015 - "The antifungal drugs used to treat candidemia are mainly the echinocandins, however some isolates may be resistant to these drugs. "
09/01/2015 - "The diminished macrophage inflammatory response to isolates that caused persistent candidemia and differential immunopharmacologic activity of echinocandins among FKS mutants suggest that certain strains of C. "
10/01/2014 - "The use of echinocandins as primary therapy for candidemia appears to be associated with better outcomes."
09/15/2014 - "Echinocandins are recommended for Candia glabrata candidemia. "
|8.||voriconazole (Vfend)FDA LinkGeneric
06/01/2004 - "Pfizer's Vfend as effective in treating candidemia as two-drug standard of care according to study."
05/01/2008 - "The present study assessed the cost-effectiveness of voriconazole for the treatment of candidemia. "
01/01/2011 - "Combination antifungal therapy with voriconazole for persistent candidemia in very low birth weight neonates."
05/01/2008 - "Results of the decision-analytical model provided evidence to support the cost-effectiveness of voriconazole relative to a regimen of CAB/FLU in the treatment of non-neutropenic patients diagnosed with candidemia in the Canadian setting."
05/01/2008 - "Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults."
|9.||Itraconazole (Sporanox)FDA LinkGeneric
11/01/2004 - "We conclude that oral itraconazole may be effective in treatment of candidemia in children in a PICU where non-C. "
11/01/2004 - "Oral itraconazole in treatment of candidemia in a pediatric intensive care unit."
02/01/1999 - "Deaths due to candidemia occurred in none of the itraconazole recipients compared with 4 placebo recipients, a difference of 2 percentage points (95% CI, 0.05% to 4%; P = .06). "
11/01/2004 - "To examine efficacy of itraconazole in the treatment of candidemia in critically ill children. "
11/01/2004 - "Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study."
03/01/2015 - "Acid-suppressant therapy does not influence absorption of azoles used in candidemia."
09/01/2014 - "Immunocompromised patients (5): Consider hepatotoxicity and interactions before starting antifungal treatment with azoles in transplanted patients; treat candidemia in neutropenic adult patients with antifungal drugs at least 14 days after the first negative blood culture and until normalization of neutrophil count is achieved. "
07/01/2014 - "Immunocompromised patients (5): consider hepatotoxicity and interactions before starting antifungal treatment with azoles in transplanted patients; treat candidemia in neutropenic adult patients with antifungal drugs at least 14 days after the first blood culture negative and until normalization of neutrophils is achieved. "
01/01/2009 - "Recent epidemiologic literature indicates that candidal species resistant to azoles are becoming more prevalent in the face of increasing incidence of hospitalizations with candidemia. "
11/01/2008 - "Antifungal prophylaxis with azoles has been demonstrated to reduce candidemia, overall mortality, and attributable mortality. "
07/01/2012 - "This finding could be attributed to a significant increase in catheter-related candidemia and better outcome, as well as to a potential improvement in the management of antifungal therapy in recent years."
10/01/2011 - "Positive blood culture is the gold standard of candidemia; it should not be accepted as contamination or colonization in children with an intravascular catheter. "
08/01/2009 - "LE-inducible candidal virulence determinants, such as germination and enhanced biofilm production, may help to explain the increased risk of candidemia in patients receiving LE via medical catheters."
04/15/2004 - "Multivariate analysis showed that catheter removal < or =72 h after onset improved response to antifungal therapy exclusively in patients with catheter-related candidemia (P=.04). "
12/01/1999 - "Data on an improved outcome of candidemia if a central venous catheter is removed promptly are conflicting. "
|2.||Transplantation (Transplant Recipients)
02/01/2008 - "dubliniensis candidemia in a heart-lung transplant recipient in Australia. "
04/01/2012 - "We report the case of a recent kidney-pancreas transplant recipient who developed a persistent catheter-related candidemia caused by Candida glabrata. "
07/01/2011 - "Some liver transplant recipients could be at risk for candidemia or invasive candidiasis during the immediate postoperative period after transplantation. "
12/01/2010 - "Of the Candida intra-abdominal infections, 41.2% developed in the first month post transplantation, while 79.5% of candidemia developed after >6 months. "
05/01/2010 - "The plasmatic levels of 1,3-beta-d-glucan (BDG) were >523 pg/ml in 4 children, 2 low-birth-weight neonates and 2 stem cell transplant recipients, with the following invasive fungal diseases (IFD) proven apart from this BDG test: 3 cases of Candida parapsilosis candidemias and 1 case of disseminated aspergillosis. "
|3.||Drug Therapy (Chemotherapy)
07/01/2014 - "The purpose of this study was to evaluate the effect of a novel "yeast-in-blood" surveillance service on the timeliness of antifungal chemotherapy for candidemia. "
08/01/1999 - "Candidemia developed mainly during aplasia in patients refractory to chemotherapy (42%). "
03/15/1999 - "The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy."
04/15/2004 - "CVC removal < or =72 h after onset should be considered in patients with suspected catheter-related candidemia who have no evidence of dissemination, recent corticosteroid therapy, or chemotherapy."
01/01/1999 - "We report three cases of candidemia due to this newly emerging Candida species in HIV-negative patients with chemotherapy-induced immunosuppression and bone marrow transplantation."
|4.||Length of Stay
11/01/2005 - "The impact of candidemia on excess mortality, increased length of stay, and the burden of cost of hospitalization underscores the need for improved means of prevention and treatment of candidemia in adults and children."
01/01/2015 - "A 1-year decision-tree model estimates hospital costs (2013 US$) and effects (candidemia-related deaths) for faster diagnostics versus blood culture (BC), accounting for disease prevalence, distribution of Candida species, test characteristics (sensitivity/specificity/time to result), antifungal medication and differential length-of-stay and mortality by appropriate treatment timing. "
02/01/2013 - "A retrospective review of 124 candidemia episodes during 2003-2008 in which all-cause and attributable mortality, length of stay and level of care were compared for patients who received and those who did not receive statins. "
11/01/2012 - "The utility of implementing the PNA FISH assay with an antimicrobial stewardship intervention in hospitalized patients with candidemia was evaluated by measuring the median time to Candida species identification, time to targeted therapy, and clinical outcomes, including time to culture clearance, hospital length of stay, and hospital mortality. "
02/01/2010 - "In addition to this high case-fatality rate, candidemia is also associated with a substantial economic burden, primarily due to an extended length of stay. "
|5.||Neck Dissection (Radical Neck Dissection)